Orthocell Limited (ASX: OCC) has appointed medical device distributor MediTime as its exclusive distributor for Remplir™ in Thailand, following regulatory approval from the Thai Food and Drug Administration to commence sales into an estimated US$84 million nerve repair market.
MediTime is a specialist orthopaedics and sports medicine distributor with established coverage across Thailand’s leading hospitals, medical schools and regional centres, and a strong commercial position in upper extremity orthopaedic surgery.
Its education-led model and established key opinion leader relationships provide Orthocell with direct access to a core customer base of orthopaedic and plastic surgeons, supporting both surgeon engagement and market adoption.
The appointment also extends Orthocell’s successful relationship with Device Technologies Group, which supports Remplir distribution in Australia, New Zealand and Singapore, and now provides regional infrastructure and commercial expertise behind MediTime’s operations in Thailand.
Orthocell CEO and MD, Paul Anderson, said:
“The appointment of MediTime as our exclusive distributor in Thailand is an important step in executing our Asian commercialisation strategy for Remplir. Thailand represents a high-quality healthcare market with strong underlying demand for advanced nerve repair solutions.
“MediTime’s established clinical relationships, education-driven model and national distribution capability make them an ideal partner to support the successful introduction of Remplir.
“Importantly, this appointment further strengthens our successful relationship with Device Technologies Group as we continue to build out our distribution network across Asia.”